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ABSTRACT
INTRODUCTION: In the last decade, platelet-rich concentrates, including the so-called platelet-rich plas-
ma (PRP), have been gaining extreme popularity and are widely used in variety of clinical fields of medi-
cine—dermatology, orthopedics, traumatology, plastic and reconstructive surgery, maxillofacial surgery, 
and others. 
AIM: The aim of the article was to analyze the quantitative characteristics of the blood components in au-
tologous platelet-rich plasma concentrates obtained by the buffy coat technique using different protocols.
MATERIALS AND METHODS: Thirty participants (avg. age 42.8) were included in the present study. Ve-
nous blood (35 mL) was drawn from each participant—3 mL were separated for control group to determine 
average blood cell level. Four protocols for PRP obtaining (4x8 mL) were performed by using vacutainer tube 
with separating gel and monovette (S-Monovette) without a separating gel. The concentration factor (%) for 
each protocol was calculated relative to the average baseline blood values of the control group.
RESULTS: Protocol I showed increase in platelet concentrations by 91.55% and the leukocyte level was 
107% higher compared to the control group. The second protocol (separating gel) demonstrated increase in 
platelet count by 337.06% and in leukocytes by 82.37%. The third protocol, based on double centrifugation, 
showed 352.08% increase in platelets and 40.54% decrease in white blood cell compared to controls. The 
fourth protocol demonstrated 389.84% increase in platelet level and 74.36% decrease in leukocyte number.
CONCLUSION: The use of separating gels into various techniques for obtaining PRP facilitates blood cell as-
piration and makes the procedure faster and safer in ambulatory practice. 
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INTRODUCTION
The administration of autologous platelet-rich 
plasma (PRP) products is defined as a revolutionary, 
alternative method in medicine. Increased prolifera-
tion and induction of human mesenchymal stem cell 
differentiation have been found to be possible expla-
nations for the clinical success reported with the use 
of autologous platelet products. Platelets excrete sev-
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eral growth factors and cytokines that are associated 
with the healing capacity and the regeneration pro-
cess in human body. Many studies demonstrate the 
chondro-inductive and osteo-inductive potential of 
PRP. Platelet-rich plasma is a general term referring 
to any sample of autologous plasma product with val-
ues  of platelet concentrations above the baseline in 
the peripheral blood (1-5). 
Depending on the different classification sys-
tems, variations in PRP products can be divided 
into several groups: pure platelet-rich plasma, plate-
let-rich and leukocyte-rich plasma, platelet-rich and 
leukocyte-poor plasma, growth factor-rich plasma, 
autologous platelet-rich plasma gel, and others. The 
terms are often mistaken and many clinicians do not 
take into account the significant differences between 
each of these blood products (6,7). Whole blood 
drawn from the patient by conventional phleboto-
my techniques is centrifuged to form a distinct mid-
dle layer that contains platelets and white blood cells 
(WBC). Thereafter, this layer is placed in the damage 
area, where growth factors and other cytokines are 
released to allow faster and more predictable regen-
eration (8,9,10). 
The buffy coat (BC) technique for obtain-
ing PRP includes the following steps (Fig. 1). Whole 
blood (8 mL) is drawn by venipuncture into vacu-
tainers with trisodium citrate as anticoagulant. The 
blood is centrifuged at high speed—above 1000×g 
(“g” centrifugal force) for a certain time at 20°C to 
24°C. Due to the different relative weight of the blood 
cells, three layers are formed: a lower layer consist-
ing of erythrocytes, a middle one consisting of plate-
lets and leukocytes, the so-called buffy coat, and a 
top layer containing platelet-poor plasma (PPP). The 
surface layer of the supernatant is removed and the 
lower 2/3 of PPP with the buffy coat layer is carefully 
aspirated and transferred to a new sterile tube with-
out anticoagulant. In order to reduce part of the leu-
kocyte count, the resulting plasma can be subjected 
to a second centrifugation with a lower centrifugal 
force—below 1000×g (11,12). There are many differ-
ent protocols for obtaining autologous platelet-rich 
products that have been described in the literature. A 
lot of commercial available kits are used, but there is 
lack of standardization and consensus on the best ap-
proach for preparation (13). 
AIM
The aim of the present study was to analyze the 
quantitative characteristics of the blood components 
in autologous PRP concentrates obtained by the 
buffy coat technique using different protocols.
MATERIALS AND METHODS
Materials
The present study had permission from the 
Ethic Committee at Medical University of Varna 
(61/30.03.2017). Thirty healthy participants (16 men 
and 14 women) at an average age of 42.8 years (min. 
26; max. 64; SD±11.840) were included in the present 
study after their informed knowledge and consent. 
In sterile manner, 35 mL of venous blood was drawn 
from each participant. Two types of laboratory con-
sumables were used. The first was vacutainer tubes 
(8 mL) with separating biocompatible gel (cycloali-
phatic polymer inert gel) and the second type was a 
monovette (S-Monovette, 8 mL) without a separat-
ing gel. Each tube had 3.2% trisodium citrate as an-
ticoagulant. The venipuncture was performed with 
a 22G needle in order to avoid premature activation 
of platelets. Three milliliters of whole blood of each 
patient were used as a control group to determine 
the baseline levels. The average values of blood cells 
(baseline levels) from the control group were com-
pared to the average values of blood cells of protocols 
I, II, III, and IV. Each blood sample was processed 
within 1 hour after its withdrawal. OHAUS Frontier 
5000 Series Multi laboratory centrifuges were used 
for the needs of the research. Symmetrical position 
of the tested tubes and calibration of the weight were 
mandatory before centrifugation. 
Fig. 1
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Methods
Four protocols for PRP obtaining based on the 
buffy coat technique were utilized and blood cell 
counts were analyzed. The first protocol involved 
single-spin centrifugation at room temperature of a 
monovette without gel for 10 minutes at 1500×g (Fig. 
2). The second protocol was under the same condi-
tions of single-spin centrifugation with relative cen-
trifugal force (RCF) of 1500×g for 10 minutes but us-
ing a vacutainer tube with a separating gel (Fig. 3). 
The third protocol included a process of double cen-
trifugation of the monovette without gel. The first 
spin (separation) had a centrifugal force of 1150×g for 
10 minutes (Fig. 4a) and the second spin (concentra-
tion) had a centrifugal force of 350×g for 5 minutes 
(Fig. 4b). The fourth protocol used 8 mL of whole 
blood in a vacutainer tube with a separating gel in 
conditions as in protocol three, namely first spin at 
RCF of 1150×g for 10 minutes (Fig. 5a) and second 
concentration spin with a centrifugal force of 350×g 
for 5 minutes (Fig. 5b) (Table 1). 
In all four protocols, after the first spin, there 
were three differentiated layers that were clearly visi-
ble. The lower layer included red blood cells, the mid-Fig. 2
Fig. 3
Fig. 4a
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dle one consisted of concentrated platelets and leu-
kocytes, and the upper layer was platelet-poor plas-
ma (PPP). The superficial PPP layer was aspirated in 
order to gain a final product of 3 mL that was ana-
lyzed. An automatic Swelab Alfa Basic hemoanalyzer 
(Boule Medical AB, Sweden) was used for measure-
ment of the platelet  number, red blood cells, neu-
trophils, lymph cells, and monocytes in the control 
group and in the PRP products obtained by different 
protocols. The concentration factor (%) relative to the 
baseline blood cells values was also calculated. 
Statistical Analyses
The data were processed with statistical soft-
ware IBM SPSS v. 20.0 for Windows, using descrip-
tive indicators for quantitative variables and present-
ed in graphics and tables. Statistically significant dif-
ference was assessed at a critical level of significance 
p<0.05. 
RESULTS
The variable conditions proposed in these ex-
perimental protocols were: centrifugation of blood 
cells with and without a separating gel; single and 
double spin; change in relative centrifugal force 
(RCF) and time. The quantity of different blood cells 
(mean; SD) from different PRP products and the ref-
erence values from control group are presented in 
Table 2. 
Results from protocol 1 showed a decrease by 
51.9% in the mean value of erythrocytes compared 
to the values of the control group, increase in plate-
let concentration by 91.55% and an increase in leu-
Fig. 4b
Fig. 5a Fig. 5b
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kocyte number by 107.21%. The second protocol in-
cluded a separating gel and demonstrated 91.42% 
decrease in the mean value of erythrocytes com-
pared to the values  of the control group, an increase 
in platelet count by 337.06% and increase in leuko-
cytes by 82.37%. The third protocol was based on a 
double centrifugation technique and showed 96.18% 
decrease in mean erythrocyte number compared to 
controls, 352.08% increase in platelet concentration 
and 40.54% decrease in white blood cells. The fourth 
protocol demonstrated 99.84% decrease in the mean 
erythrocyte count compared to the control group, 
389.84% increase in platelet counts and 74.36% de-
crease in the white blood cell number. 
DISCUSSION 
Platelet-rich plasma products have been report-
ed to play an important role in regenerative process-
es. Platelets aggregate at the damaged area and re-
lease a variety of growth factors and cytokines that 
are associated with wound healing, thereby accel-
erating the process of reparation of soft tissues and 
bone (14, 15). Examples of growth factors that are se-
creted from α-particles by the activation of platelets 
include platelet-derived growth factor (PDGF), vas-
Protocols
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Tabl. 1. Protocols for obtaining PRP with different methods




Mean Std. Dev. Mean Std. Dev. Mean Std. Dev. Mean Std. Dev. Mean Std. Dev.
RBC
×1012/L 5,01 ±0,642 2,41 ±0,547 0,43 ±0,195 0,193 ±0,041 0,008 ±0,006
PLT
×109/L 287,03 ±63,214 549,80 ±118,856 1254,50 ±274,141 1297,60 ±283,272 1406,00 ±313,091
LEU
×109/L 6,24 ±1,283 12,93 ±1,978 11,38 ±2,199 3,71 ±0,992 1,60 ±0,313
NEU
×109/L 3,60 ±0,801 6,43 ±1,389 5,82 ±1,361 0,01 ±0,009 0,005 ±0,005
Mo
×109/L 0,78 ±0,185 2,98 ±0,855 2,97 ±0,775 0,48 ±0,163 0,007 ±0,007
Ly
×109/L 2,01 ±0,458 8,88 ±2,055 8,80 ±2,022 2,23 ±0,451 1,05 ±0,138
Tabl. 2. Blood cell characteristics in various protocols and control group
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cular-endothelial growth factor (VEGF), transform-
ing growth factor-β (TGF-β), insulin-like growth 
factor (IGF) (16,17,18,19). 
Factors that can affect the quality of the PRP 
product regarding different level of blood cells are: 
number of centrifugations, temperature, RCF, and 
time (20). In the present study, the analysis and com-
parison of the level of platelets showed that the plate-
let level from protocol I was 1.91 times higher than 
baseline values in control group; in protocol II—
platelet concentration was 4.37 times higher; in pro-
tocol III (two spins)—4.52 times higher values; pro-
tocol IV (two spins/gel)—4.89 higher than the refer-
ence values. Regarding the leukocyte level, protocol 
I and II showed higher values in comparison to the 
control group—2.01 times and 1.75 times, respective-
ly. Protocols that had two spins showed significant 
decrease in leukocyte number compared to the ini-
tial values: for method III—1.73 lower, method IV—4 
times lower than the reference values. 
For clinical application based on these data, 
surgeons should consider the individual necessities 
of the patient and the technical requirements for PRP 
preparation. It can be a time-consuming and expen-
sive procedure. Protocols II, III, and IV showed sig-
nificant enrichment of platelets in the PRP products. 
If a leukocyte-poor product is needed, then double 
centrifugation methods are recommended (proto-
col III or IV), if leukocyte-rich product is desired for 
clinical application, protocols with one centrifuga-
tion should be used (protocol II). We should empha-
size that regarding tissue healing, there is no consen-
sus about positive or negative effects of leukocytes in 
PRP. Some studies proposed that leukocytes stim-
ulate the healing process in damaged tissue and si-
multaneously suppress the growth of some bacteria 
(21,22). On the other hand, a lot of studies showed 
positive correlation between the total number of leu-
kocytes in PRP and increased levels of pro-inflam-
matory cytokines, indicating that leukocytes in PRP 
may inhibit the healing process (23,24).
Future perspectives should focus on analyzing 
the quantity of different growth factors in PRP prod-
ucts and its correlation to platelet and leukocyte lev-
els (25,26). In contrast to commercial devices, an ad-
vantage of a standard clinical centrifuge is the ability 
to change force and time parameters and thus the fi-
nal product can be affected depending on the desired 
clinical application
CONCLUSION
Platelet-rich plasma is an autologous product 
that facilitates the healing of soft tissues and bone af-
ter surgical treatment and procedures. Platelet-rich 
plasma is a general term, these products have specif-
ic variations in their structure and as a result—dif-
ferent use for clinical application is recommended. 
The use of separating gels facilitates blood cell aspi-
ration and makes the procedure faster in ambulato-
ry practice. The optimal concentration of platelets, 
leukocytes, and other plasma components remains 
to be clarified and the researcher should be aware 
that the PRP effect is not only based on thrombocyte 
concentration.
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